Share

Postmenopausal Women May Benefit from Estrogen Compound Research

Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A high-fat diet further exacerbates the disease, which can progress to cirrhosis and liver failure. Hormone replacement therapy (HRT) is an effective treatment, but it carries increased risk of breast cancer, uterine cancers, and cardiovascular disease. Researchers...
Share

Endocrine Society Advocates for Increased Immunization Rates

With flu season in full swing, the Endocrine Society encourages its members to help “Raise the Rates” and increase adult immunization rates among their patients. Raise the Rates is an initiative led by the American College of Physicians (ACP) to help internists and other primary care providers in both understanding the immunization rates of their...
Share

EU Chemicals Strategy Advances Endocrine Society EDC Priorities

As the European Commission makes progress towards implementation of the Chemicals Strategy for Sustainability (CSS), the Endocrine Society continues to provide input to ensure that the strategy modernizes the European Union’s approach to identification and regulation of endocrine-disrupting chemicals (EDCs). Our members are providing feedback in several different ways, including as a member of the...
Share

New Stem Cell-Derived Treatment for Type 1 Diabetes Shows Promising Results in New Studies

Positive preliminary results of an ongoing, first-in-human Phase 1/2 study demonstrating that stem cell-derived therapy can produce insulin in people with severe type 1 diabetes were published today in Cell Stem Cell and Cell Reports Medicine. “The data from these papers represent a significant scientific advance,” said Cell Reports Medicine study lead author James Shapiro, MD PhD, Canada...
Share

Medicare Releases Physician Fee Schedule Final Rule for 2022

The Center for Medicare and Medicaid Services (CMS) released its final rule for the Medicare Physician Fee Schedule (MPFS) for calendar year 2022. Earlier this year, the Endocrine Society provided detailed comments on the proposed rule. While we still have serious concerns, several of our recommendations to benefit endocrinologists were incorporated into the final rule....
Share

Transgender Women May Be More Prone to Type 2 Diabetes than Cisgender Women

Trends_JCEM Transgender women may be at higher risk for type 2 diabetes compared to cisgender women, but not to cisgender men, according to new research published in The Journal of Clinical Endocrinology & Metabolism. Nearly 1 million people identify as transgender in the U.S., and healthcare providers are encountering more transgender and gender-diverse patients in their practices. An important priority of transgender health research is to...
Share

2021 Advocacy Year in Review

The Endocrine Society advocates on behalf of our members, the patients they treat, and the science they research. Though our work in 2021 remained virtual, we successfully advocated for our policy priorities and raised the visibility of the value of endocrinology and endocrine research. Let’s look back at some of our wins from this year....
Share

European Medicine Agency’s CHMP Grants Positive Opinion to Long-Acting Growth Hormone for Patients with Pediatric Growth Hormone Deficiency

In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...